The Food and Drug Administration (FDA) has expanded the approval of Furoscix® (furosemide injection) to include the treatment of edema in patients with ...

The Furoscix 80 mg/10 ml subcutaneous injection is intended for oedema in adult CKD patients, including those with nephrotic ...

Furosemide injection was previously approved to treat congestion from fluid buildup in adults with chronic heart failure.

Cardiorenal specialist scPharmaceuticals has won US Food and Drug Administration (FDA) approval for its supplemental New Drug Application (sNDA) for Furoscix (furosemide injection) to expand the ...

TD Cowen analyst Stacy Ku maintained a Buy rating on scPharmaceuticals (SCPH – Research Report) today and set a price target of $25.00.Discover ...

Investment analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of scPharmaceuticals in a ...

Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable ...

Pharmaceuticals (SCPH) announced that the FDA has approved the supplemental new drug application for Furoscix to expand the indication to ...

The market expects Regenxbio (RGNX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...

ScPharmaceuticals, Inc. (SCPH) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

BURLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the "Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient ...